Diseases of the liver related to metabolic syndrome have emerged as the most common and undertreated hepatic ailments. The cause of nonalcoholic fatty liver disease is the aberrant accumulation of lipid in hepatocytes, though the mechanisms whereby this leads to hepatocyte dysfunction, death, and hepatic fibrosis are still unclear. Insulin-sensitizing thiazolidinediones have shown efficacy in treating nonalcoholic steatohepatitis (NASH), but their widespread use is constrained by dose-limiting side effects thought to be due to activation of the peroxisome proliferator-activated receptor c. We sought to determine whether a next-generation thiazolidinedione with markedly diminished ability to activate peroxisome proliferator-activated receptor c (MSDC-0602) would retain its efficacy for treating NASH in a rodent model. We also determined whether some or all of these beneficial effects would be mediated through an inhibitory interaction with the mitochondrial pyruvate carrier 2 (MPC2), which was recently identified as a mitochondrial binding site for thiazolidinediones, including MSDC-0602. We found that MSDC-0602 prevented and reversed liver fibrosis and suppressed expression of markers of stellate cell activation in livers of mice fed a diet rich in trans-fatty acids, fructose, and cholesterol. Moreover, mice with liver-specific deletion of MPC2 were protected from development of NASH on this diet. Finally, MSDC-0602 directly reduced hepatic stellate cell activation in vitro, and MSDC-0602 treatment or hepatocyte MPC2 deletion also limited stellate cell activation indirectly by affecting secretion of exosomes from hepatocytes. Conclusion:
T he epidemic of obesity has dramatically increased the incidence of a variety of related metabolic diseases, including nonalcoholic fatty liver disease (NAFLD).
(1) NAFLD encompasses a spectrum of diseases from isolated steatosis to steatohepatitis (NASH), which includes steatosis with inflammation, hepatocyte ballooning injury, and fibrosis. (2) NASH is a leading cause of cirrhosis and liver failure, (2) increases risk for hepatocellular carcinoma, (3) and is currently the second leading indication for liver transplantation in the United States. (4, 5) Fibrosis, and thus parenchymal remodeling, is the best predictor of progression, need for liver transplant, and mortality. (6) (7) (8) Despite the prevalence of NAFLD and
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the related public health problems, there are currently no approved medical therapies beyond weight loss and exercise, (9, 10) which are difficult to achieve and maintain. (11) Pioglitazone (Actos) and rosiglitazone (Avandia) have been used clinically as insulin-sensitizing agents and evaluated for their effects on NASH in experimental models and clinical trials. Thiazolidinediones (TZDs) reduced liver injury, lowered circulating transaminases, and improved histologic measures of NASH. (12) (13) (14) (15) (16) (17) Recently, pioglitazone was shown to reverse hepatic fibrosis and other NASH measures in an 18-month trial. (18) TZDs elicit many of their effects by serving as activating ligands for the nuclear receptor peroxisome proliferator-activated receptor c (PPARc). (19) While these drugs are clearly effective insulin sensitizers and anti-inflammatories, their use is limited by a number of known side effects that are also mediated through activation of PPARc. (20) Recently, we postulated that some of the beneficial effects of TZDs might be separable from their ability to activate PPARc and have developed "PPARc-sparing" TZDs (MSDC-0602 and MSDC-0160), which have limited ability to bind and activate PPARc but retain the beneficial metabolic effects, (21, 22) even in hepatocytes with complete deletion of PPARc. (21) TZDs also bind to the mitochondrial pyruvate carrier (MPC) at physiological concentrations (23, 24) and acutely suppress pyruvate metabolism in isolated mitochondria in an MPC-dependent manner. (24, 25) The MPC comprises two proteins, MPC1 and MPC2, that form a carrier complex in the inner mitochondrial membrane. (26) Transport into the mitochondrial matrix is required for pyruvate metabolism and critical for a number of metabolic pathways. The effects of MSDC-0602 on reducing hepatocyte glucose production in vitro were abolished in MPC2-deficient hepatocytes, (24) suggesting that at least some of the beneficial metabolic effects of this PPARc-sparing TZD are mediated through an interaction with MPC2.
The objective of the present study was to determine whether MSDC-0602 might have therapeutic effects in an experimental model of NASH and, if so, to define whether binding to the MPC was involved. We found that MSDC-0602 treatment reduced histologic fibrosis, toxic lipid accumulation, and molecular markers of hepatic stellate cell activation in mice. We showed that these effects were dependent on MPC2 and that hepatocyte-specific deletion of MPC2 by itself was protective from the development of liver injury. Finally, we showed that MSDC-0602 directly prevents stellate cell activation in vitro and acts indirectly to regulate activation by modulating exosome release by hepatocytes in an MPC2-dependent manner. These data demonstrate the effectiveness of MSDC-0602 at reducing liver fibrosis and stellate cell activation through effects on MPC2 and suggest that targeting the MPC is a potential therapeutic avenue for treating NASH.
Materials and Methods

ANIMAL STUDIES
All animal experiments were approved by the Animal Studies Committee of the Washington University School of Medicine and comply with the criteria outlined in the Guide for the Care and Use of Laboratory Animals by the National Academy of Sciences. Wildtype C57BL6/J male mice were purchased from Jackson Laboratories. LS-Mpc2 -/-mice in the C57BL6/J background have been described. (24) Littermate mice not expressing Cre (fl/fl mice) were used as controls. All diet studies were initiated in mice 6-9 weeks old.
Male mice were placed on a diet enriched with fat (40% kcal, mainly trans-fat; trans-oleic and translinoleic acids), fructose (20% kcal), and cholesterol
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(2% w/w) (HTF-C diet; D09100301; Research Diets Inc.), described to cause hepatic injury and inflammation. (27) Control mice were fed a matched low-fat (LF; 10% kcal) diet that was not supplemented with fructose or cholesterol (D09100304; Research Diets Inc.). (28) After remaining on the designated diets for 4 weeks, a subset of randomly selected HTF-C-fed mice were placed on the HTF-C diet containing MSDC-0602 potassium salt (331 ppm) for the remaining 12 weeks prior to sacrifice. This dose was chosen based on studies showing that 331 ppm in the diet resulted in a concentration of 2-5 lM MSDC-0602 in the blood of obese mice (unpublished observation), was effective at insulin sensitizing, (21) and compared with plasma exposures examined in clinical trials. (29) In a second trial, diet feeding was for a total of 19 weeks, and a fourth group of mice was placed on the plain HTF-C diet for 16 weeks and then switched to HTF-C 1 331 ppm MSDC-0602 for the remaining 3 weeks.
Body weight was checked weekly. Mice were sacrificed and tissues were harvested after a 4-hour fast. Liver, gonadal, subcutaneous, and intrascapular brown fat tissue samples were weighed, frozen in liquid nitrogen, and stored at -808C.
MATERIALS
Production-scale synthesis of all TZDs for mouse studies was conducted by USV (Mumbai, India), and TZDs were incorporated into the experimental diets by Research Diets Inc.
PLASMA AND LIVER CHEMISTRIES
Plasma alanine transaminase (ALT) and aspartate transaminase (AST) were measured by kinetic absorbance assays (Teco Diagnostics). Liver triglycerides were measured by solubilizing 100 mg liver tissue in saline and solubilizing lipid with 0.5% sodium deoxycholate and determined by colorimetric assay (Thermo Fisher Scientific).
HISTOLOGIC ANALYSES
Liver sections were fixed in 10% neutral buffered formalin for 24 hours and then embedded in paraffin blocks. Sections were cut and stained with either hematoxylin and eosin or Masson's trichrome stain. Livers were analyzed by a liver pathologist (either E.M.B. or I.N.), blinded to treatment group and genotype. Steatosis, inflammation, hepatocyte ballooning, and fibrosis were scored according to NAFLD activity score (NAS) and fibrosis scoring. (30) 
MASS SPECTROMETRY AND LIPID QUANTIFICATION
Oxidative stress markers (oxysterols and organic aldehydes) were extracted with methanol from homogenized liver tissues and quantified by a liquid chromatography-mass spectrometry (Shimadzu and Applied Biosystems) system using deuterated compounds (in-house preparation and Cayman Chemical) as internal standards and methods as described. (31) Protein concentrations in the liver homogenates were also determined by bicinchoninic acid assay (Pierce) for normalization.
QUANTITATIVE RT-PCR
Total RNA was isolated using the RNAzol method (RNA-Bee; Tel-Test). Complementary DNA was made by use of a high-capacity reverse-transcription kit for liver tissues (Applied Biosystems) and a Vilo reverse-transcription kit for isolated stellate cells (Invitrogen). Real-time PCR was performed using an ABI PRISM 7500 sequence detection system and a SYBR green master mix (Applied Biosystems). Arbitrary units of target mRNA were corrected by measuring the levels of 36B4 mRNA. Oligonucleotide sequences are available upon request.
REPORTER SENSITIVE TO PYRUVATE
Potential drug interactions with the MPC were assessed using a bioluminescence energy transfer (BRET)-based MPC activity system called reporter sensitive to pyruvate (RESPYR). (32, 33) Briefly, described MPC2-RLuc8 and MPC1-Venus fusion proteins were stably expressed in HEK293 cells using lentiviral transduction. Assays were performed as published, (32, 33) with the addition of drug compounds after baseline readings in the absence of pyruvate. Bioluminescence and energy transfer were assessed using a kinetic plate reader (Biotek Synergy 2) at 460 6 40 nm and 528 6 20 nm at 378C.
STELLATE CELL ISOLATION AND CULTURE
Primary mouse hepatic stellate cells were isolated by collagenase perfusion during hepatocyte isolations. (24) Stellate cells were then purified by density gradient centrifugation using Optiprep (Sigma) as described. (34) Cells were seeded onto standard six-well tissue culture dishes and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 13 Pen/Strep. A subset of cells was harvested after 24 hours to serve as quiescent control cells. All other cells were treated as indicated and harvested after 3-7 days. (34) EXOSOME ISOLATION, WESTERN BLOTTING, AND STELLATE CELL TREATMENT Plasma exosomes were enriched from frozen plasma collected at the end of the HTF-C diet feeding trials. Plasma (500 lL) was first defibrinated using purified thrombin, and then exosomes were purified using ExoQuick reagent (System Biosciences). For western blotting analysis, whole blood or plasma exosome samples were solubilized in 25 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid, 150 mM NaCl, 1 mM ethylene diamine tetraacetic acid, and 1% Triton X-100 protein lysate buffer. Protein lysates (75 lg) were run down polyacrylamide gels and transferred onto polyvinylidene fluoride membranes. Membranes were then probed with primary antibodies for the vesicle marker flotillin-1 (1:500, ab50671; Abcam) and the cell marker calnexin (1:1,000, ab22595; Abcam). Membranes were then probed with an antirabbit IRDye 800CW secondary antibody (1:10,000; LI-COR), and blots were developed on an infrared Odyssey developer (LI-COR). For stellate cell treatments, exosome pellets were solubilized in 300 lL phosphatebuffered saline, and day 2 stellate cell six-well cultures were treated with either phosphate-buffered saline vehicle control or exosomes for 24 hours before harvest for RNA analyses.
STATISTICAL ANALYSES
Statistical comparisons were made using a t test or analysis of variance where appropriate. All data, unless otherwise specified, are presented as mean 6 standard error of the mean, with a statistically significant difference defined as P 0.05.
Results
MSDC-0602 IMPROVES LIVER INJURY INDUCED BY HTF-C FEEDING IN MICE
Diets containing high levels of trans-fat in the context of elevated fructose and/or cholesterol provoke liver injury and development of fibrosis in mice. (27, 28, 35) We fed the HTF-C diet to C57BL6/J mice for 16 weeks and evaluated hepatic steatosis and liver injury. Compared to a matched LF control diet, the HTF-C diet induced significant weight gain (Fig. 1A) and adiposity (Supporting Fig. S1A,B) . The HTF-C diet also caused an increase in the liver to body weight ratio (Fig. 1B) and increased liver triglyceride content (Fig.  1C) . In a subset of mice, the HTF-C diet was fed for 4 weeks, and then MSDC-0602 was added to the HTF-C diet for the remaining 12 weeks (HTF-C10602). MSDC-0602 feeding suppressed body weight gain (Fig. 1A) and adiposity (Supporting Fig.  S1A ,B) independently of changes in food intake (Supporting Fig. S1C ). The attenuation in body weight gain and adiposity was correlated with a marked increase in the mass of intrascapular brown adipose tissue (Supporting Fig. S1D ), consistent with MSDC-0602 directly stimulating differentiation of brown adipocyte progenitor cells (23) and suggesting that increased energy expenditure explains the effects on body weight. However, this aspect of the phenotype was not explored further. MSDC-0602 did not reverse the effects of HTF-C on liver to body weight ratios (Fig. 1B) or improve the hepatic triglyceride accumulation observed with HTF-C feeding (Fig. 1C) , allowing measurements of inflammation, hepatocyte ballooning, and fibrosis to be made in an unbiased manner.
Plasma ALT and AST concentrations were markedly increased by the HTF-C diet (Fig. 1D) . However, MSDC-0602 significantly improved plasma ALT and AST concentrations, suggesting decreased liver injury. Histologic evidence of steatosis, hepatocyte ballooning, and inflammatory cell infiltration was observed in HTF-C diet-fed livers ( Fig. 2A) . Ductular reactions involving progenitor cells and matrix deposition were readily apparent in HTF-C livers ( Fig. 2A, arrow) . Collagen or matrix deposition was also abundant in HTF-C livers ( Fig. 2A, arrowhead) and appeared reduced in livers of MSDC-0602-fed animals. When analyzed by a histopathologist blinded to treatment groups, the NAS (sum of steatosis 1 ballooning 1 inflammation) was significantly elevated by the HTF-C diet and reduced by MSDC-0602 (Fig. 2B) . Fibrosis scoring was also significantly elevated by the HTF-C diet and reduced by MSDC-0602 (Fig. 2B) . Interestingly, although triglyceride accumulation was not quantitatively affected (Fig. 1C) , treatment with MSDC-0602 restored characteristic zonality to lipid deposition, with periportal zone 1 hepatocytes being spared from steatosis ( Fig. 2A) . The mechanisms driving this effect can only be speculated upon; perhaps being related to greater drug effectiveness in zone 1 due to higher tissue perfusion, oxygen tension, and anabolic metabolism (36) or differences in lipid profiles (37) of periportal zone 1 hepatocytes. Additionally, expression of cytochrome P450 and other xenobiotic metabolizing enzymes is higher in perivenous zone 3 hepatocytes, (36) suggesting greater drug metabolism and lower drug effectiveness in zone 3 hepatocytes. Of note, the appearance of the remaining zone 2 and 3 steatosis is not significantly altered, with most hepatocytes containing a mixture of microsteatosis and macrosteatosis.
Liver samples were analyzed by mass spectrometry for lipid markers of oxidative stress. The HTF-C diet caused elevated levels of oxysterols 7-ketocholesterol and 3b,5a,6b-cholestantriol, as well as the organic aldehydes hydroxynonenal and hydroxyhexanol (Fig.  3A) . MSDC-0602 feeding either tended to or significantly reduced these lipid markers of oxidative stress. Lastly, liver gene expression markers of inflammatory cytokine production, macrophage infiltration, hepatic stellate cell activation, and fibrosis were also increased by HTF-C diet feeding (Fig. 3B) . MSDC-0602 treatment did not improve markers of inflammation or macrophage infiltration (Tnfa, Tgfb, Il1b, Cd68, and Thbs1). However, MSDC-0602 significantly improved markers of stellate cell activation, fibrosis, and extracellular matrix remodeling (Col1a1, Col3a1, Spp1, Timp1, Timp3, and Mmp2) (Fig. 3B) . These data strongly suggest that MSDC-0602 alleviates oxidative stress, stellate cell activation, and matrix deposition in mice fed an HTF-C diet.
MSDC-0602 REVERSES LIVER INJURY INDUCED BY HTF-C FEEDING
We also sought to determine whether MSDC-0602 could reverse, as opposed to prevent, diet-induced liver injury and stellate cell activation by beginning drug treatment after 16 weeks on diet, when liver injury and fibrosis is fully manifest. Switching HTF-C mice to HTF-C chow containing MSDC-0602 for 3 weeks beginning at 16 weeks caused significant weight loss (Fig. 4A ). Providing mice with chow containing Liver NAS (the sum of steatosis, ballooning, and inflammation scores) as well as fibrosis scoring was performed by a trained pathologist blinded to treatment group. Values are mean 6 standard error of the mean. n 5 10, *P < 0.05 versus LF-fed group, † P < 0.05 versus HTF-C fed group. MSDC-0602 starting at 4 weeks slightly reduced liver triglyceride content, while 3 weeks of MSDC-0602-containing diet had no effect on liver triglycerides (Fig.  4B) . However, both long-term and short-term MSDC-0602 treatment significantly reduced plasma ALT and AST concentrations (Fig. 4C) and improved NAS and fibrosis scoring (Fig. 4D,E) . As observed in the previous trial, early switch to a diet containing MSDC-0602 strongly reduced markers of stellate cell fibrogenesis (Fig. 4F) . Additionally, the 3 weeks of treatment with MSDC-0602 significantly reduced all markers of stellate cell fibrogenesis and extracellular matrix regulation (Fig. 4F) .
MSDC-0602 INTERACTS WITH THE MPC
MSDC-0602 and other TZDs bind to the MPC complex and reduce flux through this carrier. (24, 25) To demonstrate a direct interaction between MSDC-0602 and the MPC, we used the recently described RESPYR system (32) (Fig. 5A) . Interaction with pyruvate, the substrate of the MPC, leads to a conformational change and an increase in energy transfer in this BRET-based sensor. (32) Interestingly, a high-potency, irreversible MPC inhibitor (UK-5099) also produces a robust increase in RESPYR activity (Fig. 5B) . Similarly, addition of MSDC-0602 or MSDC-0160 provoked a significant increase in RESPYR activity (Fig.  5B) . We believe that these chemical MPC inhibitors result in increased BRET activity due to their interaction with the same binding pocket of the MPC as pyruvate, inducing a similar conformational change in the complex. In contrast, another TZD compound that lacks insulin-sensitizing properties (MSDC-1473) (23) fails to stimulate RESPYR activity (Fig. 5B) . Dose-response curves demonstrated that MSDC-0602 was 100-fold less potent than UK-5099 and failed to elicit the same maximal increase in RESPYR activity (Fig. 5C ). These data are consistent with a direct interaction between MSDC-0602 and the MPC, though the affinity of binding and/or mechanism of interaction may be different from other traditional inhibitors.
MICE WITH LIVER-SPECIFIC DELETION OF MPC2 ARE REFRACTORY TO LIVER INJURY INDUCED BY THE HTF-C DIET AND THE EFFECTS OF MSDC-0602
To examine the effects of loss of MPC function on the response to the HTF-C diet and MSDC-0602, we used mice with liver-specific deletion of MPC2. (24) There was no effect of this mouse genotype on weight gain on the HTF-C diet, and loss of MPC in the liver did not affect the ability of MSDC-0602 to suppress weight gain (Fig. 6A) . Loss of MPC activity in liver resulted in reduced circulating ALT and AST in HTF-C-fed mice, and the ability of MSDC-0602 to reduce plasma transaminase activity was lost in liver MPC2 null mice. Similarly, fibrosis scoring and the expression of markers of stellate cell activation were also suppressed by genetic loss of MPC in liver, and MSDC-0602 did not further repress the expression of these genes in LS-Mpc2 -/-mice (Fig. 6C,D) . MSDC-0602 tended to reduce fibrosis scoring in the knockout. However, this was not significant (P 5 0.13). Interestingly, this improvement in hepatic fibrosis with genetic deletion of MPC2 was despite no improvement in hepatic steatosis as liver triglyceride levels were unaltered (Fig. 6E) . Thus, both genetic deletion and pharmacologic inhibition of the MPC appear to improve hepatic fibrosis without significantly altering hepatic steatosis in this HTF-C diet-induced NASH model.
DIRECT AND INDIRECT EFFECTS OF MSDC-0602 ON STELLATE CELL ACTIVATION
One of the most consistent phenotypes across our mouse studies was that MSDC-0602 suppressed expression of the markers of stellate cell fibrogenesis. Treatment of isolated stellate cells with MSDC-0602 during the 7-day in vitro differentiation process moderately reduced expression of the stellate cell fibrotic markers Col1a1 and Col3a1 (Fig. 7A) . Values are presented as the mean 6 standard error of the mean. n 5 7-9, except for n 5 6 per group in (F). *P < 0.05 versus LF-fed group, † P < 0.05 versus HTF-C fed group, 1 P < 0.05 comparing the MSDC-0602 @4 and @16 groups. Abbreviations: AU, arbitrary units; TAG, triacylglyceride.
We found that genetic deletion of Mpc2 in the liver also led to reduced activation of stellate cells in vivo (Fig. 6C,D) . It has been suggested that the albumin promoter may be active in stellate cells and leads to Cre-mediated recombination in that cell type. (38) To determine whether Mpc2 expression was affected in stellate cells of LS-Mpc2 -/-mice, we isolated hepatocytes and stellate cells from these mice. In our hands, while the LS-Mpc2
-/-hepatocyte fraction shows the expected deletion of Mpc2, (24) its expression was not 
affected in LS-Mpc2
-/-stellate cells in either the day 1 quiescent or day 7 activated state ( Fig. 7B) . This suggests that the beneficial effects of genetic inhibition of Mpc2 in LS-Mpc2 -/-mice were likely not mediated through direct effects in stellate cells. Taken together with the modest effect of MSDC-0602 on stellate cell activation in vitro (Fig. 7A) , these data suggest that the effects of modulating MPC2 specifically in hepatocytes may produce an antifibrotic paracrine signal that contributes to the reduced stellate cell activation.
SUPPRESSION OF STELLATE CELL ACTIVATION MAY BE MEDIATED BY HEPATOCYTE-DERIVED EXOSOMES
Recent work has suggested that extracellular vesicles, called "exosomes," that are released by hepatocytes and other cell types can signal to stellate cells by transferring DNA, RNA, protein, or lipid contents. (39) (40) (41) (42) (43) Increased exosome release by steatotic hepatocytes in vitro and in vivo has also been suggested. (44, 45) Therefore, we next isolated exosome-enriched plasma fractions from our LF diet-fed and HTF-C diet-fed mice to test whether a paracrine signal was being released from hepatocytes to stellate cells to affect fibrogenesis. The plasma exosome samples were enriched for the membrane vesicle marker flotillin-1 and devoid of the cell marker calnexin (Fig. 7C) . When stellate cell cultures were treated with these plasma exosome fractions between days 2 and 3 of culture, plasma exosomes isolated from HTF-C-fed mice increased the expression of Col1a1, Col3a1, Mmp2, and Timp1 in stellate cells isolated from naive wild-type mice (Fig. 7D) . However, plasma exosomes isolated from mice fed the HTF-C diet containing MSDC-0602 failed to enhance the expression of these genes (Fig. 7D) . Lastly, plasma exosomes from HTF-C diet-fed LS-Mpc2 -/-mice also reduced the expression of stellate cell fibrogenic markers in comparison to plasma exosomes from HTF-C diet-fed wild-type mice (Fig. 7E) . Altogether, these data suggest that MSDC-0602 treatment or genetic deletion of MPC2 in hepatocytes modifies exosomes containing or lacking a factor that subsequently controls stellate cell activation status.
Discussion
Available evidence suggests a strong interconnection among insulin resistance, hepatic steatosis, and development of NASH. Indeed, a number of studies have suggested that insulin-sensitizing TZDs may have efficacy for treating NASH and potentially even reverse hepatic fibrosis. (12) (13) (14) (15) (16) (17) (18) In this study, we evaluated the efficacy of a next-generation TZD that has extremely weak binding to PPARc but still directly interacts with and inhibits the MPC. We found that MSDC-0602 prevented and reversed stellate cell activation and fibrosis in a mouse model of NASH. Moreover, we show that loss of the MPC2 protein in mouse hepatocytes also has similar protective effects on these parameters. The present in vivo and in vitro findings suggest that modulating MPC activity in hepatocytes leads to production of signaling factor(s) that regulate stellate cell activation and fibrogenesis.
Whereas we did observe a direct effect of MSDC-0602 on stellate cell activation in vitro, several other findings in this study suggest that drug effects on the expression of these genes are also mediated through effects in hepatocytes. Indeed, exosomes isolated from plasma of HTF-C diet-fed mice promoted expression of markers of stellate cell activation in vitro, while exosomes from MSDC-0602-treated or MPC2 knockout mice did not. The caveat is that exosomes isolated from plasma could be derived from any organ and the drug effect may not be specific to the liver. However, the data with exosomes isolated from LS-Mpc2 -/-mice strongly suggest that hepatocyte-derived exosomes play an important role in this response. In support of our findings, an unidentified signal released from steatotic hepatocytes has been proposed to induce hepatic stellate cell activation. (46) We also found that MPC2, which is up-regulated in stellate cells during activation, was not deleted in stellate cells from LSMpc2 -/-mice. This indicates that the albumin promoter is not active in stellate cells in our hands, which contrasts with a recent report (38) but is consistent with a paracrine factor being elicited from MPC2-deficient hepatocytes.
It remains to be determined what cargo of exosomes is responsible for communicating with stellate cells in this model of NASH and in our pharmacologic and genetic manipulations. Exosomes are small lipid vesicles that contain a variety of materials including lipids, proteins, and RNAs. (47) Delivery and uptake of these vesicles to other cells is a relatively recently identified mechanism of cell-to-cell communication, and this process is incompletely understood. It has been suggested that hepatocyte-derived exosomes can regulate stellate cell activation. (39) (40) (41) (42) (43) Candidate mediators would include mitochondrial DNA (43) ; microRNAs including let-7, miR-122-5p, (41) and miR-214 (39, 40) ; and other noncoding RNAs. (42) Future studies will be needed to identify the mediator(s) that signals between hepatocytes and stellate cells in our system, as well as how altering hepatocyte pyruvate metabolism leads to these beneficial effects on exosome cargo.
In summary, the present data suggest that the novel insulin-sensitizer MSDC-0602 has beneficial pharmacological effects to prevent and reverse stellate cell activation and fibrosis in a mouse model of NASH. Importantly, the effects of this agent, which has inhibitory effects on the activity of the MPC, were recapitulated by genetic deletion of MPC2 in hepatocytes and lost when MPC2 was deleted. The data presented herein support a model that hepatocyte-derived exosomes mediate a beneficial effect of MPC2 deletion on stellate cell activation. Though more work is needed to completely understand mechanisms and mediators, the present data support further studies using MPC modulators for treating NASH.
